必斯芬替啶 | 96153-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 必斯芬替啶
• 中文别名: 比芬替丁
• 英文名称: N-Isopropyl-N'-[4-(2-methyl-imidazol-4-yl)phenyl]-formamidine
• 英文别名: bisfentidine；N-[4-(2-methyl-1H-imidazol-5-yl)phenyl]-N'-propan-2-ylmethanimidamide
• CAS: 96153-56-9
• 化学式: C₁₄H₁₈N₄
• 分子量: 242.324
• InChiKey: FXJAOWANXXJWGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

文献信息

• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Carboxylic acid derivates
  申请人：GLAXO GROUP LIMITED

  公开号：EP0367484A1

  公开（公告）日：1990-05-09

  The invention relates to salts formed between basic H₂-­receptor antagonists and a complex of bismuth with a carboxylic acid, and solvate of such salts, excluding salts in which the basic H₂-receptor antagonist is ranitidine. Examples of suitable carboxylic acids are citric acid and tartaric acid. Examples of basic H₂-­receptor antagonists are cimetidine, sufotidine famotidine and nizatidine. The salts ares useful in the treatment of gastrointestinal disorders, particularly gastroduodenal conditions. The salts show the antisecretory activity associated with the basic H₂-receptor antagonist together with antibacterial activity against Campylobacter pylori and they also possess cytoprotective properties.

  本发明涉及碱性 H₂受体拮抗剂和铋与羧酸的络合物之间形成的盐类，以及此类盐类的溶液，不包括碱性 H₂受体拮抗剂为雷尼替丁的盐类。合适的羧酸有柠檬酸和酒石酸。碱性 H₂受体拮抗剂的例子有西米替丁、磺胺脒、法莫替丁和尼扎替丁。 这些盐类可用于治疗胃肠道疾病，特别是胃十二指肠疾病。这些盐类显示出与基本 H₂受体拮抗剂相关的抗分泌活性以及对幽门弯曲杆菌的抗菌活性，它们还具有细胞保护特性。
• Carboxylic acid derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0454449A1

  公开（公告）日：1991-10-30

  The invention relates to salts formed between basic H2-receptor antagonists and a complex of zinc with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, and to solvates of such salts, excluding salts in which the basic H2-receptor antagonist is ranitidine. Examples of basic H2-receptor antagonists are cimetidine, famotidine, nizatidine and roxatidine. The salts are useful in the treatment of gastrointestinal disorders, such as peptic ulcer disease and non-ulcer dyspepsia.

  本发明涉及碱性 H2 受体拮抗剂和锌与选自酒石酸、柠檬酸和烷基柠檬酸的羧酸的络合物之间形成的盐，以及此类盐的溶液，不包括碱性 H2 受体拮抗剂为雷尼替丁的盐。碱性 H2 受体拮抗剂的例子有西咪替丁、法莫替丁、尼扎替丁和罗沙替丁。 这些盐类可用于治疗胃肠道疾病，如消化性溃疡病和非溃疡性消化不良。
• A method of applying an oral composition
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1393710A1

  公开（公告）日：2004-03-03

  The present invention relates to a method of applying oral care benefit agent to the oral tissues. More specifically, a method for treating an oral cavity is provided comprising the application of an aqueous composition comprising oral care benefit agents to a large proportion of the oral cavity, application occurring as part of the daily oral care routine shortly before retiring, and the composition remaining in contact with the oral tissues while sleeping. The method and aqueous compositions of the invention provide overnight application and delivery of oral care benefit agents with improved ease of use and consumer aesthetics

  本发明涉及一种向口腔组织施用口腔护理剂的方法。更具体地说，本发明提供了一种治疗口腔的方法，包括将含有口腔护理剂的水性组合物涂抹在口腔的大部分区域，涂抹作为退休前不久的日常口腔护理程序的一部分，组合物在睡眠时与口腔组织保持接触。本发明的方法和水性组合物提供了口腔护理益处剂的隔夜应用和递送，并改善了使用的便利性和消费者的审美观